| Literature DB >> 31455238 |
Vera A van Atteveld1, Jeanine M Van Ancum1, Esmee M Reijnierse2, Marijke C Trappenburg3,4, Carel G M Meskers1,5, Andrea B Maier6,7.
Abstract
BACKGROUND: Chronic inflammation is considered to affect physical performance, muscle strength and muscle mass, i.e. measures of sarcopenia. We need to identify a marker of inflammation that is univocally associated with measures of sarcopenia. We aimed to associate three markers of inflammation, erythrocyte sedimentation rate, albumin and white blood cell count, with measures of sarcopenia in geriatric outpatients.Entities:
Keywords: Albumin; Blood sedimentation; Inflammation; Muscular atrophy; Outpatients; Sarcopenia; White blood cells
Mesh:
Substances:
Year: 2019 PMID: 31455238 PMCID: PMC6712841 DOI: 10.1186/s12877-019-1253-5
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Patient characteristics
| Characteristics |
| Total ( |
|---|---|---|
| General | ||
| Age, years | 442 | 80.8 (6.7) |
| Sex, female, n (%) | 442 | 257 (58.1) |
| Living independently, n (%) | 421 | 367 (87.2) |
| Education, years, median [IQR] | 380 | 10 [9–13] |
| Use of alcohol, n (%) | 408 | 255 (62.5) |
| Current smoking, n (%) | 410 | 43 (10.5) |
| Polypharmacy, n (%)* | 441 | 257 (58.3) |
| Anti-inflammatory medication, n (%)† | 440 | 36 (8.2) |
| Number of morbidities, median [IQR] | 441 | 3 [2–4] |
| MMSE score, median [IQR] | 425 | 26 [22–28] |
| Weight, kg | 413 | 70.2 (13.5) |
| Height, cm | 414 | 166.6 (9.7) |
| BMI, kg/m2 | 408 | 25.3 (4.2) |
| Hemoglobin, mmol/L | 435 | 8.6 (0.9) |
| Anemia, n (%) | 435 | 83 (19.1) |
| Functional status | ||
| Katz ADL score, median [IQR] | 399 | 0 [0–1] |
| Use of walking aid, n (%) | 408 | 169 (41.4) |
| Immobile > 1 week in last 3 months, n (%) | 387 | 59 (15.2) |
| Maximal walking distance, > 1 km, n (%) | 391 | 140 (35.8) |
| Fall in past year, n (%) | 404 | 246 (60.9) |
| Inflammatory markers | ||
| ESR, mm/hr., median [IQR] | 408 | 11 [6–22] |
| Albumin, g/L, median [IQR] | 433 | 37.8 [35.7–39.7] |
| WBC count, E9/L, median [IQR] | 442 | 7.2 [6.0–8.7] |
| Measures of sarcopenia | ||
| Gait speed, m/s | 419 | 0.8 (0.3) |
| TUG test, s, median [IQR] | 303 | 14.9 [11.5–19.0] |
| CST, s, median [IQR] | 356 | 13.6 [11.4–18.6] |
| HGS, kg | 423 | 22.2 (9.6) |
| RMM, % | 68 | 36.7 (5.4) |
| ALM/height2, kg/m2 | 68 | 7.1 (1.2) |
All variables are presented as mean (standard deviation), unless otherwise specified
ADL Activities of daily living, ALM Appendicular lean mass, BMI Body mass index, CST Chair stand test, ESR Erythrocyte sedimentation rate, HGS Handgrip strength, IQR Interquartile range, MMSE Mini-mental state examination, RMM Relative skeletal muscle mass, TUG Timed up and go, VAS Visual analogue scale, WBC White blood cell
*Polypharmacy: use of > 4 medication
†Anti-inflammatory medication: use of prednisone, prednisolone, methotrexate, mesalazine, hydroxychloroquine, infliximab or non-steroid anti-inflammatory drugs
Outcomes of linear regression analysis of the association between ESR, albumin and WBC count with measures of sarcopenia
| Gait speed, m/s | Ln TUG test, s | Ln CST, s | HGS, kg | RMM, % | ALM/height2, kg/m2 | ||
|---|---|---|---|---|---|---|---|
| ESR | Crude β 95% CI | −0.005 −0.007, −0.003 | 0.006 0.003, 0.010 | 0.005 0.002, 0.008 | −0.126 −0.189, −0.063 | −0.179 −0.274, −0.084 | −0.000 −0.022, 0.022 |
|
|
|
|
|
| 1.000 | ||
| Adjusted β 95% CI | −0.004 −0.006, −0.002 | 0.005 0.002, 0.008 | 0.005 0.002, 0.008 | −0.052 −0.102, −0.001 | −0.115 −0.196, −0.034 | 0.010–0.011, 0.031 | |
|
|
|
|
|
| 0.328 | ||
| Albumin | Crude β 95% CI | 0.020 0.011, 0.028 | −0.020 −0.034, −0.006 | −0.012 −0.025, 0.001 | 0.596 0.311, 0.881 | 0.233–0.244, 0.711 | 0.002–0.101, 0.106 |
|
|
| 0.062 |
| 0.333 | 0.962 | ||
| Adjusted β 95% CI | 0.014 0.006, 0.022 | −0.013 −0.027, 0.000 | −0.009 −0.022, 0.004 | 0.455 0.225, 0.684 | 0.375–0.014, 0.764 | − 0.007 −0.102, 0.088 | |
|
| 0.057 | 0.166 |
| 0.059 | 0.886 | ||
| WBC count | Crude β 95% CI | −0.011 −0.021, − 0.002 | 0.011–0.005, 0.026 | 0.002–0.012, 0.016 | −0.354 −0.679, − 0.029 | −0.654 −1.362, 0.055 | − 0.105 −0.263, 0.053 |
|
| 0.178 | 0.785 |
| 0.070 | 0.188 | ||
| Adjusted β 95% CI | −0.005 −0.014, 0.004 | 0.006–0.009, 0.021 | − 0.001 −0.015, 0.013 | −0.112 −0.371, 0.146 | − 0.430 −1.017, 0.156 | −0.071 −0.214, 0.071 | |
| 0.299 | 0.409 | 0.921 | 0.393 | 0.147 | 0.322 | ||
ALM Appendicular lean mass, β Beta, CI Confidence interval, CST Chair stand test, ESR Erythrocyte sedimentation rate, HGS Handgrip strength, Ln Natural logarithm, RMM Relative skeletal muscle mass, TUG Timed up and go, WBC White blood cell. Adjusted model: adjusted for age, sex, number of morbidities. Bold indicates a statistical significant outcome
Fig. 1Erythrocyte sedimentation rate tertiles and measures of sarcopenia. Bars: Estimated means, adjusted for age, sex and number of morbidities. Error bars: 1 standard error. Level of significance based on linear regression: * p ≤ 0.05; ** p < 0.01; *** p < 0.001. ALM Appendicular lean mass, CST Chair stand test, ESR Erythrocyte sedimentation rate, HGS Handgrip strength, Ln Natural logarithm, RMM Relative skeletal muscle mass, TUG Timed up and go